8582 Background: Leptomeningeal metastases (LM) present with a high incidence in EGFR-
mutated NSCLC following treatment with first-or second-generation EGFR TKIs. Osimertinib …

PURPOSE Leptomeningeal metastases (LMs) exhibit a high incidence in patients with
epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) post …

PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

In this open-label phase II clinical trial, patients with EGFR-mutated non–small cell lung
cancer (NSCLC) who had developed leptomeningeal metastases (LM) after treatment with …

In this open-label phase II clinical trial, patients with EGFR-mutated non–small cell lung
cancer (NSCLC) who had developed leptomeningeal metastases (LM) after treatment with …

Advanced non‐small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) is
associated with a dismal prognosis of typically 3‐9 months. In preclinical and clinical …

2020 Background: LM due to NSCLC progression are associated with poor prognosis.
Osimertinib is an oral, CNS-active, irreversible EGFR-TKI selective for sensitizing (EGFRm) …

Methods In this Phase II multicenter, open-label, single-arm study, 80 mg osimertinib was
administered to patients with EGFR-mutated NSCLC who had developed LM subsequent to …

Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …

Background The aim of this study was to evaluate the efficacy and safety of osimertinib for
the treatment of leptomeningeal metastases (LM) from epidermal growth factor receptor …